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Sutureless aortic tissue valves have been introduced several years ago as an alternative to stented or 
stentless bioprostheses for the treatment of aortic stenosis. Initial reports and current evaluation of 
the clinical performance suggests that this new technology – after a carefully organized training 
phase - is safe and allows a quicker procedure with shorter cross-clamp and cardiopulmonary bypass 
duration. In addition, peri- and early postoperative complication rates are not higher than those 
observed after conventional surgical approach. 
Until recently, three different models fabricated by three different companies (Enable® from ATS-
Medtronic, Minneapolis, MN; USA, Perceval® from Sorin, Saluggia, Italy and Intuity® from Edwards 
Lifesciences, Irvine, CA, USA) have been on the market, but in November 2014, Medtronic issued a 
Field Safety Notice (FSN) to alert physicians regarding the risk of migration with the 3f Enable Aortic 
Bioprosthesis (Model 6000): the company modified the Instructions for use (IFU) to recommend the 
use of two tied-off guiding sutures. While the revised instructions in the FSN continue to show 
positive outcomes, the product has seen limited commercial adoption. Therefore, Medtronic has 
decided to discontinue the 3f Enable Aortic Bioprosthesis (Model 6000) and the related accessories 
as well as cease the training and proctoring of any new implanters. How could this happen? Some 
results were disappointing since complications like migration of the device and paravalvular leakage 
appeared instead of reducing cross-clamp and cardiopulmonary bypass duration due to rapid 
deployment. I had personally excellent clinical results with the 3-f Enable valve over the last 10 years 
(1,2) but I always advocated a careful proctoring and teaching of new centers as well as the 
establishment of a registry and the publication of a consensus regarding indications, potential pitfalls 
and unexpected events with this type of devices. In previous publications, there was a significant 
heterogeneity in outcomes such as paravalvular leaks and valve degeneration, which may reflect the 
varying degrees of technical experience between individual institutions and the divergent efficacy 
and safety between different types of sutureless valve types (3). Therefore, instead of improving the 
surgical outcome and facilitating the minimally invasive approach in higher risk patients, the results 
reported by some surgical teams were less than optimal and the devices remained controversially 
discussed and not adopted by a large number of surgeons.  
For this reason, the present recommendations of an international consensus panel are welcome in 
order to clarify some practical issues and to further define the role of sutureless technologies in the 
broad field of surgical valvular devices (4). Among several interesting findings, the authors of this 
document exactly emphasize the fact that meticulous proctoring and training are mandatory for the 
sutureless technology, on both an institutional as well as individual level.   
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From a total of 1300 publications, only 80+ papers were cleared for the final appreciation. This is a 
classical finding in the cardiac surgical literature: this particular surgical domain lacks from 
randomized multicenter studies as compared with those available in interventional cardiology. For 
the purposes of this paper, the authors focus on observations in different institutions.  
Which types of valvular replacement devices does the surgical community want to have available? 
The answer is rather simple: a valve easy for manipulation, reproducible during implantation, and 
proven good quality with stable long-term results. For special cases, e.g. those with a previous 
homograft in aortic position, sutureless technology might be the ideal alternative, because the 
device can be implanted once the degenerated leaflets of the homograft have been removed. The 
vascular part of the homograft stays in, of course. Another important indication may be for high-risk 
and multimorbid and/or older patients who need a combined procedure with anticipated longer 
ischemic time.  
The work done by this international group of experts is the first step in the right direction. This paper 
has to be followed by additional work collected with increased experience with this type of valve.  
As a cardiac valve substitute, sutureless prostheses avoid suturing after annular decalcification, 
thereby reducing aortic cross-clamp and cardiopulmonary bypass duration and facilitating a 
minimally invasive approach.  While there is current data supporting reduced surgical operative 
times with sutureless AVR [5,6], whether the use of this technology results in improved clinical 
outcomes remains uncertain. Unfortunately, multiple outcomes are still not adequately reported, 
including resource-related outcomes such as intensive care unit stay, hospitalization duration, cost-
effectiveness and quality of life outcomes (2). Such parameters are also of critical importance when 
considering SU-AVR as an alternative to conventional AVR and perhaps TAVI as well. The lack of 
randomization, blinding and comparators in the included studies indicates an inherent source of 
unaccounted bias, which may have skewed the presented results. Another major limitation of the 
current knowledge on sutureless valves is the absence of long-term data beyond 4 years. Long-term 
studies are also required to compare SU-AVR with conventional AVR and TAVI approaches, 
particularly in the setting of high-risk patients, to determine whether SU-AVR is safe and efficacious, 
and which approach offers more clinical advantages for each individual patient. 
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